Clincosm LogoSign in Get a demo

Metabolic Disorders in Polycystic Ovarian Syndrome

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT00172523
Collaborator
(none)
1
Location
10
Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to elucidate the significance of adipocytokine in women with PCOS among adiposity, hyperandrogenism and insulin resistance.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age with a probable prevalence of 5% to 10%. PCOS is characterized by chronic anovulation, menstrual irregularities, evidence of hyperandrogenism (either clinical, manifested as hirsutism, acne, male pattern balding, or biochemical, manifested by elevated serum adrenal and/or ovarian androgen concentration). Fifty percent of all patients with PCOS are obese, and the presence of obesity affects the clinical manifestations of PCOS. The underlying pathogenic mechanisms appear to involve insulin resistance and hyperinsulinemia, the magnitude of which is greater in obese than in non-obese women with PCOS.

    Study Design

    Study Type:
    Observational
    Observational Model:
    Defined Population
    Time Perspective:
    Other
    Study Start Date :
    Oct 1, 2004
    Study Completion Date :
    Aug 1, 2005

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      17 Years to 40 Years
      Sexes Eligible for Study:
      Female
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
        1. Oligomenorrhea ( less than 6 times spontaneous MC per year) or Amenorrhea. 2. Hyperandrogenism (either clinical or biochemistry. 3. PCO by ultrasound. 4.After menarche, before menopause.
      Exclusion Criteria:
        1. hormone therapy in the past 6 months. 2. Pregnancy in the past 6 months 3.Acute illness found in the past 3 months. 4.Systemic disease including autoimmune disease, malignancy, hepatic, renal or CVS disease, and ever received chemotherapy or immunosuppressive agents.

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Department of Obstetrics and Gynecology, National Taiwan University Hospital Taipei Taiwan

      Sponsors and Collaborators

      • National Taiwan University Hospital

      Investigators

      • Study Director: Horng-Nerng Ho, M.D., NTUH

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      , ,
      ClinicalTrials.gov Identifier:
      NCT00172523
      Other Study ID Numbers:
      • 9361701094
      First Posted:
      Sep 15, 2005
      Last Update Posted:
      Sep 15, 2005
      Last Verified:
      Oct 1, 2004
      Additional relevant MeSH terms:
      Polycystic Ovary Syndrome
      Syndrome

      Study Results

      No Results Posted as of Sep 15, 2005